Fibroblast growth factors and their receptors in urological cancers: Basic research and clinical implications

被引:84
作者
Cronauer, MV [1 ]
Schulz, WA [1 ]
Seifert, HH [1 ]
Ackermann, R [1 ]
Burchardt, M [1 ]
机构
[1] Univ Dusseldorf, Dept Urol, D-40225 Dusseldorf, Germany
关键词
fibroblast growth factors; urological cancers; clinical implications;
D O I
10.1016/S0302-2838(03)00005-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Because therapeutical options for advanced urological cancers are limited, the understanding of key elements responsible for invasion and metastasis is very important. It has been hypothesized that progression to malignant growth is associated with a dysregulation of growth factors and/or their receptors. In the last few years, signaling pathways of the fibroblast growth factor (FGF) family have been subject to intense investigation. Fibroblast growth factors constitute one of the largest families of growth and differentiation factors for cells of mesodermal and neuroectodermal origin. The family comprises two prototypic members, acidic FGF (aFGF) and the basic FGF (bFGF), as well as 21 additionally related polypeptide growth factors that have been identified to date. FGFs are involved in many biological processes during embryonic development, wound healing, hematopoesis, and angiogenesis. In prostate, bladder, and renal cancers, FGFs regulate the induction of metalloproteinases (MMP) that degrade extracellular matrix proteins, thus facilitating tumor metastasis. Probably due to their potent angiogenic properties, aFGF and bFGF have received the most attention. However, there is increasing evidence that other FGFs also play crucial roles in tumors of the prostate, bladder, kidney, and testis. This review will discuss the different elements involved in FGF signaling and summarize the present knowledge of their biological and clinical relevance in urological cancers. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:309 / 319
页数:11
相关论文
共 133 条
  • [1] Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo
    Aigner, A
    Renneberg, H
    Bojunga, J
    Apel, J
    Nelson, PS
    Czubayko, F
    [J]. ONCOGENE, 2002, 21 (37) : 5733 - 5742
  • [2] Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO
  • [3] 2-H
  • [4] EXPRESSION OF BASIC FIBROBLAST GROWTH-FACTOR AND ITS RECEPTOR IN AN INVASIVE BLADDER-CARCINOMA CELL-LINE
    ALLEN, LE
    MAHER, PA
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 1993, 155 (02) : 368 - 375
  • [5] FIBROBLAST GROWTH FACTOR-II (FGF-2) IN THE NUCLEUS - TRANSLOCATION PROCESS AND TARGETS
    AMALRIC, F
    BOUCHE, G
    BONNET, H
    BRETHENOU, P
    ROMAN, AM
    TRUCHET, I
    QUARTO, N
    [J]. BIOCHEMICAL PHARMACOLOGY, 1994, 47 (01) : 111 - 115
  • [6] Intravenous basic fibroblast growth factor (bFGF) decreases DNA fragmentation and prevents downregulation of Bcl-2 expression in the ischemic brain following middle cerebral artery occlusion in rats
    Ay, I
    Sugimori, H
    Finklestein, SP
    [J]. MOLECULAR BRAIN RESEARCH, 2001, 87 (01): : 71 - 80
  • [7] BAIRD A, 1991, PEPTIDE GROWTH FACTO, V1, P368
  • [8] Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors
    Billerey, C
    Chopin, D
    Aubriot-Lorton, MH
    Ricol, D
    de Medina, SGD
    Van Rhijn, B
    Bralet, MP
    Lefrere-Belda, MA
    Lahaye, JB
    Abbou, CC
    Bonaventure, J
    Zafrani, ES
    van der Kwast, T
    Thiery, JP
    Radvanyi, F
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) : 1955 - 1959
  • [9] T-LYMPHOCYTES SYNTHESIZE AND EXPORT HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH-FACTOR AND BASIC FIBROBLAST GROWTH-FACTOR, MITOGENS FOR VASCULAR CELLS AND FIBROBLASTS - DIFFERENTIAL PRODUCTION AND RELEASE BY CD4+ AND CD8+ T-CELLS
    BLOTNICK, S
    PEOPLES, GE
    FREEMAN, MR
    EBERLEIN, TJ
    KLAGSBRUN, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (08) : 2890 - 2894
  • [10] FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate
    Bowe, AE
    Finnegan, R
    de Beur, SMJ
    Cho, J
    Levine, MA
    Kumar, R
    Schiavi, SC
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 284 (04) : 977 - 981